Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
03 janv. 2024 06h30 HE
|
Agios Pharmaceuticals, Inc.
–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of Change From...
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
02 janv. 2024 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
09 déc. 2023 19h00 HE
|
Agios Pharmaceuticals, Inc.
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
20 nov. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy...
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
02 nov. 2023 09h05 HE
|
Agios Pharmaceuticals, Inc.
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support...
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
02 nov. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK...
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
19 oct. 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
29 août 2023 07h00 HE
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced...
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
03 août 2023 06h35 HE
|
Agios Pharmaceuticals, Inc.
Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease; On Track to Enroll First Patient in Phase 3 Portion of the Study in Q4 2023 ...
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
03 août 2023 06h30 HE
|
Agios Pharmaceuticals, Inc.
– Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios’ Scientific Expertise and Capabilities in Rare Hematologic Diseases...